Studienname, Substanz, primärer Endpunkt (CVOT)			Sekundärer Endpunkta
	Prim. Endpunkt	MACE	Gesamt Mortalität	CV-Mortalität	Myokardinfarkt	Insult	Hosp. wg. Herzinsuffizienz	Renale Endpunkteb
EMPA-REG-OUTCOME, Empagliflozin	↓(3-MACE)	↓	↓	↓	=	=	↓	↓
CANVAS, Canagliflozin	↓(3-MACE)	↓	=	=	=	=	↓	↓
DECLARE, Dapagliflozin	↓(kardiovaskulärer Tod und HHI)	=	=	=	=	=	↓	↓
VERTIS-CV, Ertugliflozin	= (3-MACE)	=	=	=	=	=	↓	=
ELIXA, Lixisenatid	= (4-MACE)	=	=	=	=	=	=	n.b.
EXCSEL, Exenatid	= (3-MACE)	=	↓	=	=	=	=	n.b.
LEADER, Liraglutid	↓(3-MACE)	↓	↓	↓	=	=	=	↓
SUSTAIN‑6, Semaglutid s.c.	↓(3-MACE)	↓	=	=	=	↓	=	↓
REWIND, Dulaglutid	↓(3-MACE)	↓	=	=	=	↓	=	↓
PIONEER‑6, Semaglutid oral	= (3-MACE)	=	↓	↓	=	=	=	n.b.
SAVOR TIMI, Saxagliptin	= (3-MACE)	=	=	=	=	=	↑	=
EXAMINE, Alogliptin	= (3-MACE)	=	=	=	=	=	=	=
TECOS, Sitagliptin	= (4-MACE)	=	=	=	=	=	=	=
CARMELINA, Linagliptin	= (3-MACE)	=	=	=	=	=	=	=
UKPDS, Metformin Studie; Follow Up	↓(komb. Endpunkt)c	n.b.	↓	=	↓	=	=	=
PROACTIVE, Pioglitazon	= (komb. Endpunkt)d	↓	=	=	↓	↓	↑	=
ORIGIN, Glargin	= (3-MACE)	=	=	=	=	=	=	=
DEVOTE, Degludec	= (3-MACE)	=	=	=	=	=	=	=

CVOT cardiovascular outcomes trial, n.b. nicht berichtet

^a Hypothesengenerierend

^b Wie in der Hauptpublikation definiert

^c Jegliche Diabetes-bezogene klinische Endpunkte, Diabetes-bezogener Tod, Gesamtmortaltität

^d Kombinierter Endpunkt aus Gesamtmortalität, nicht-tödlichem Herzinfarkt, (einschließlich stummer Infarkte), nicht-tödlichem Schlaganfall, akutes Koronarsyndrom, endovaskuläre oder chirurgische Intervention der Koronarien oder Beinarterien, Amputation über dem Knöchel